Efficacy and safety of rituximab as second-line therapy in immune thrombocytopenic purpura based on ethnicity: A descriptive study among the Arabic population.

Autor: Ata F; Department of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar E-mail: fata@hamad.qa; docfateenata@gmail.com., Yousaf Z; Department of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar E-mail: fata@hamad.qa; docfateenata@gmail.com., Zahir FZ; Department of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar E-mail: fata@hamad.qa; docfateenata@gmail.com., Mohamed Babiker A; Department of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar E-mail: fata@hamad.qa; docfateenata@gmail.com., Ali Farooqi A; Department of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar E-mail: fata@hamad.qa; docfateenata@gmail.com., Ahmad Al Hiyari M; Department of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar E-mail: fata@hamad.qa; docfateenata@gmail.com., Al Bozom AI; Department of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar E-mail: fata@hamad.qa; docfateenata@gmail.com., Mohamed AH; Department of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar E-mail: fata@hamad.qa; docfateenata@gmail.com., Nashwan AJ; Department of Nursing for Education & Practice Development, Hamad Medical Corporation, Doha, Qatar., Yassin MA; Department of Medical Oncology/Hematology, National Centre for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.

Publikováno v: Qatar medical journal [Qatar Med J] 2022 Jul 07; Vol. 2022 (3), pp. 22. Date of Electronic Publication: 2022 Jul 07 (Print Publication: 2022).